Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-936558 (Nivolumab) with SBRT in Cholangiocarcinoma
NCT04648319Phase 2Terminated
- Sponsor
- American University of Beirut Medical Center
- Start
- Apr 2021
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of nivolumab in cholangiocarcinoma (CCA), sponsored by American University of Beirut Medical Center. Started Apr 2021; status: terminated.
02
Drugs
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04648319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04648319.